Merck Animal Health Showcases New Research Advancing Ruminant Health at World Buiatrics Congress
September 29, 2026
58 studies highlighted advances across areas including neonatal calf health, respiratory disease prevention and livestock monitoring technologies
RAHWAY, N.J., Sept. 29, 2026 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), presented more than 50 new studies at the 33rd World Buiatrics Congress in Istanbul, Turkey. The company presented data spanning the continuum of ruminant health, from neonatal calf health and early calf development to respiratory health, infectious diseases, parasitology, herd management and monitoring technologies, including seven oral presentations, 51 poster presentations and a sponsored symposium on calf health.
Research presented at the congress highlighted a comprehensive body of evidence examining maternal vaccination against Cryptosporidium parvum and its potential role in supporting neonatal calf health. The data include research exploring the mechanism of GP40-mediated passive immunity, studies evaluating antibody transfer from vaccinated dams to calves, and field investigations assessing calf health outcomes and the frequency of therapeutic interventions following maternal vaccination. Together, these findings contribute to a growing understanding of how preventive approaches may support calf health while potentially reducing the need for intervention. Additional presentations highlighted advancements in respiratory disease prevention, responsible antibiotic use and automated monitoring technologies designed to support data-driven herd management decisions
“Our presence at the World Buiatrics Congress reflects Merck Animal Health’s commitment to advancing science that is both rigorous and directly relevant to the challenges veterinarians and producers face every day,” said Tiago Arantes, associate vice president of the global ruminant business at Merck Animal Health. “The breadth of research highlights our leadership in bovine health and our commitment to generating meaningful science with real-world impact, demonstrating how science can help veterinarians and producers make more informed decisions and improve outcomes.”
Advancements in Neonatal Calf Health and Cryptosporidiosis Prevention
Neonatal calf diarrhea remains one of the most significant health challenges affecting cattle operations worldwide. Research presented will explore the science behind GP40-mediated passive immunity, maternal vaccination against C. parvum, antibody transfer through colostrum and transition milk, and field outcomes related to calf health, therapeutic interventions and disease management. Together, these studies contribute to a growing body of evidence supporting comprehensive approaches to improving neonatal calf health. Key presentations included:
Unravelling the Mechanism of GP40-Mediated Passive Immunity Against Cryptosporidiosis
Research explores the biological mechanisms through which GP40-specific antibodies may contribute to passive protection against C. parvum infection in calves.
Longitudinal Multicenter Field Trial Evaluating the Serological Response to Maternal Vaccination Against Cryptosporidium parvum in Newborn Holstein-Friesian Calves
A multicenter field study evaluates antibody responses in newborn calves following maternal vaccination against cryptosporidiosis.
The Effect of Vaccinating Cows Against Cryptosporidiosis on the Frequency of Therapeutic Interventions in Calves
Researchers evaluate the impact of maternal vaccination on the frequency of therapeutic interventions in calves under field conditions.
Control of Neonatal Cryptosporidiosis in Large Dairy Farms Using Maternal GP40 Vaccination and Extended Transition Milk Feeding: A Potential Alternative to Metaphylaxis?
This study examines maternal vaccination and extended transition milk feeding as part of an integrated strategy for managing neonatal cryptosporidiosis.
Medium-Term Follow-Up of Neonatal Cryptosporidiosis Control in Beef Cattle Through Dam Vaccination: Impact on Calf Health, Paromomycin Use and Growth
Findings evaluate the longer-term impact of dam vaccination on calf health outcomes, antimicrobial use and growth performance in beef herds.
Farmer Compliance with Maternal Vaccination Against Neonatal Calf Diarrhea (Cryptosporidium parvum): A Field Evaluation
Research examines adoption and implementation of maternal vaccination programs under commercial farm conditions.
Respiratory Disease Prevention and Bovine Coronavirus Research
Bovine respiratory disease continues to present a substantial challenge to cattle health and productivity. Presentations explored the role of bovine coronavirus within the respiratory disease complex, field outcomes associated with intranasal vaccination strategies and approaches that may support responsible antibiotic use. Highlights included:
Simultaneous Intranasal Vaccination Against Bovine Respiratory Syncytial Virus, Parainfluenza-3 Virus, and Bovine Coronavirus Reduces Antibiotic Use in Dutch Veal Calf Settings
A multicenter historical-control study examines the association between simultaneous intranasal vaccination and antibiotic use in Dutch veal calf operations.
Randomized Field Trial on the Effects of On-Arrival Intranasal Vaccination Against Bovine Coronavirus on Ultrasound-Confirmed Pneumonia and Average Daily Gain in Beef-on-Dairy Veal Calves
Researchers evaluate respiratory health and growth outcomes following on-arrival intranasal vaccination against bovine coronavirus.
Efficacy of an Intranasal Bovine Coronavirus Vaccine on Lung Health and Growth Performance in Pre-Weaned Calves
A field study evaluates lung health and average daily gain in pre-weaned calves following intranasal bovine coronavirus vaccination.
New Kid on the Block? Bovine Coronavirus Detection in Different Types of Respiratory Samples and Interactions with Other Pathogens and Season
Research examines bovine coronavirus detection in different respiratory samples, interactions with other pathogens and seasonal patterns.
Smart Farming and Youngstock Monitoring
Automated monitoring technologies like SenseHub Dairy provide continuous behavioral and activity monitoring that generate actionable insights to support cattle health, reproduction and herd management. Several presentations and posters explored how animal behavior data can be used to optimize youngstock management, facilitate the early detection of sick animals from birth to adulthood, improve understanding of calf development, and identify relationships between early-life behavioral patterns and long-term performance outcomes, including:
From Data to Decisions: A Qualitative Study on the Day-to-Day Use of Youngstock Health Monitoring Sensors in Dairy Farming
Researchers explore how farmers use youngstock monitoring technologies in routine dairy management and the factors influencing their integration.
Cattle Care 24/7: A Holistic Approach Combining Monitoring, Consultation and Preventive Solutions Improving Calf Health and Average Daily Gain on Five Danish Dairy Farms
The study evaluates an approach combining monitoring, consultation and preventive solutions on five Danish dairy farms.
Early Rumination as a Functional Indicator of the Transition From Milk-Fed Calf to Ruminant
Research evaluates the relationship between early rumination behavior and subsequent growth performance in dairy calves.
The company also hosted a satellite symposium, Starting Strong: Managing Neonatal Calf Diarrhea with New Insights and Proven Practice, which explored current scientific understanding of neonatal calf diarrhea and practical, evidence-based strategies to support calf health.
About Merck Animal Health
Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is a global animal health business committed to The Science of Healthier Animals™. For more than 130 years, we have pioneered groundbreaking science. Today, we are driven by continuous innovation to develop breakthrough medicines, vaccines and technology. Rooted in direct experience on the farm and in the clinic, we work hand in hand with our customers every step of the way. Our singular focus is to empower those who care for animals, helping them manage their vital responsibility with confidence. Because when it comes to animal health, no one sees it like we do. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen